18th Jul 2012 13:49
18 July 2012
Cyprotex PLC
Result of AGM
Cyprotex PLC (AIM:CRX), the drug discovery ADME Tox services and information company, today announces that at the Company's AGM yesterday all the resolutions were duly passed. The results of the proxy votes lodged in advance of the AGM are now available on Cyprotex's website.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
|
|
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 203 205 7500 |
Shaun Dobson Claes Spang
| www.singercm.com |
|
|
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Simon Conway Mo Noonan | www.fticonsulting.com
|
Notes to Editors:
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
Related Shares:
CRX.L